As of Apr 24
| -0.18 / -1.29%|
The 4 analysts offering 12-month price forecasts for Supernus Pharmaceuticals Inc have a median target of 14.00, with a high estimate of 16.00 and a low estimate of 11.00. The median estimate represents a +1.74% increase from the last price of 13.76.
The current consensus among 4 polled investment analysts is to Buy stock in Supernus Pharmaceuticals Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.